Latest / Business Strategy Talks with Fexingo: Competitive Advantage, Market Positioning, and Growth Planning
How Novo Nordisk Built a Moat in Diabetes and Weight Loss
In this episode, Lucas and Luna explore how Novo Nordisk created an almost unassailable competitive advantage in diabetes care and obesity treatment. They trace the company's century-long focus on protein engineering, the strategic bet on GLP-1 drugs like semaglutide, and the manufacturing moat that now takes competitors years to replicate. With a market cap exceeding $600 billion as of mid-2026, Novo Nordisk has become Europe's most valuable company. The conversation drills into specific numbers: 50% market share in global insulin, a 10-year head start in GLP-1 production capacity…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.